Ozempic Lawsuit
semaglutide · injection
The most-filed claim. Approved for type 2 diabetes in 2017 and widely prescribed off-label for weight loss.
Novo Nordisk
If Ozempic, Wegovy, Mounjaro or another GLP-1 drug left you with gastroparesis (stomach paralysis), a bowel obstruction, gallbladder surgery or sudden vision loss, you may be able to sue Novo Nordisk or Eli Lilly. 4,128 Ozempic lawsuits are pending in federal court right now. Tell us what happened and we will match you with an Ozempic lawyer who handles these claims — free, and with no obligation.
Counts come straight from the JPML’s published docket report. We re-pull it monthly. Check the source yourself.
In most cases, yes — if a doctor diagnosed you with a qualifying injury while you were taking the drug and your medical records back it up. Ozempic lawsuits are product liability claims for failure to warn. They argue that Novo Nordisk and Eli Lilly knew, or should have known, that GLP-1 drugs could cause severe stomach and bowel injuries and optic nerve damage, and that their warning labels did not say so clearly enough.
You are not suing your doctor and you are not suing your pharmacy. You are suing the manufacturer. And you are not joining a class action — you would be filing your own individual lawsuit, valued on your own injuries, inside a group of similar cases called an MDL.
You do not have to have taken Ozempic specifically. The litigation covers the whole GLP-1 class, from both manufacturers, whether it was prescribed for type 2 diabetes or for weight loss.
The most-filed claim. Approved for type 2 diabetes in 2017 and widely prescribed off-label for weight loss.
Same active ingredient as Ozempic, licensed specifically for weight management. Same injuries, same dockets.
Eli Lilly’s GLP-1/GIP drug for type 2 diabetes. Included in MDL 3094 alongside the Novo Nordisk products.
The weight-loss version of Mounjaro. Newer to the docket, but claims are being accepted.
The tablet form of semaglutide. Digestive injury claims are treated the same as the injectable.
An earlier GLP-1 for weight management, also named in the multidistrict litigation.
Eli Lilly’s weekly GLP-1 for type 2 diabetes, covered by the same failure-to-warn claims.
Harder. These claims usually run against the compounder or seller, not the manufacturer. Tell us where you got it.
No — and this is the single most common misunderstanding about these cases. People search for an “Ozempic class action lawsuit” because that is the familiar phrase, but that is not what this is.
In a class action, one case covers everybody and a single pot of money is divided up, so what happened to you individually barely affects what you receive. In an MDL, which is what the Ozempic litigation actually is, you keep your own lawsuit. Your damages are calculated from your own medical records, your own bills and your own losses. Two people in the same docket routinely recover very different amounts.
The practical consequence: nobody is enrolled automatically. There is no class you belong to by default and no claim form to fill in. If you do nothing, you recover nothing — you have to file your own case, which is why people hire an Ozempic lawyer.
In December 2025 the Judicial Panel split GLP-1 claims in two. The injuries, the medical experts and the qualifying evidence are entirely different, so the court runs them as separate proceedings — before the same judge.
The older and much larger docket. Centralised in February 2024 with 37 cases, it now grows by more than a hundred new filings a month. Covers Novo Nordisk and Eli Lilly products alike.
Created on 15 December 2025 for claims that semaglutide caused non-arteritic anterior ischemic optic neuropathy — a stroke of the optic nerve that usually leaves permanent sight loss in one eye.
If you suffered both a digestive injury and vision loss, you may have a claim in each docket. They are filed and evaluated separately — one does not roll into the other.
GLP-1 drugs work partly by slowing how fast the stomach empties. The claims argue the manufacturers understood where that mechanism could lead and did not say so clearly enough.
The stomach stops emptying properly. Relentless nausea, vomiting undigested food hours after eating, bloating, pain and weight loss. For some people it does not resolve after stopping the drug.
Filed in MDL 3094The intestine stops moving contents along. Often an emergency — many claimants were hospitalised, and some needed surgery. The FDA added ileus to the Ozempic label in 2023.
Filed in MDL 3094Inflammation, stones and gallbladder removal surgery. Frequently pleaded alongside the other digestive injuries rather than on its own.
Filed in MDL 3094Blood flow to the optic nerve is cut off, usually overnight and without pain. Most people wake with a permanent blind area in one eye. Sight rarely returns.
Filed in MDL 3163Repeating bouts of severe vomiting separated by symptom-free stretches. Often severe enough to cause dehydration and repeat emergency visits.
Filed in MDL 3094Severe upper abdominal pain radiating to the back, with nausea and vomiting. Acute and necrotising pancreatitis claims are pleaded alongside the other digestive injuries.
Filed in MDL 3094Where a digestive injury or its complications contributed to a death, surviving family may bring a claim. The deadline runs from the date of death, on its own clock.
Either docketMost people arrive with a diagnosis and no idea whether it counts. Describe what happened and we will check it against both dockets and your state’s deadline.
Check my eligibilityNobody can confirm this from a web page, but these are the lines the litigation actually draws - and the evidence rule below decides more claims than anything else.
On 15 August 2025 the court ruled that gastroparesis claims in MDL 3094 need to be backed by a gastric emptying study, the scan that objectively measures how fast your stomach empties. A doctor writing “gastroparesis” in your notes is no longer enough on its own.
This is the single most common reason a GLP-1 claim gets rejected. If you were never sent for that scan, say so early — sometimes it can still be arranged, and other injuries such as ileus and bowel obstruction are held to different requirements.
Every entry below is a matter of public court record or published research, not a projection.
The Judicial Panel consolidates 37 federal GLP-1 digestive-injury cases in the Eastern District of Pennsylvania. The docket has grown by more than a hundred filings a month ever since.
A study in JAMA Ophthalmology reports that patients with type 2 diabetes taking semaglutide had roughly four times the risk of NAION, and weight-loss patients around seven times. Both manufacturers dispute that this shows causation.
The European Medicines Agency’s safety committee concludes NAION is a very rare side effect of semaglutide and recommends adding it to European product labels.
Judge Marston rules that gastroparesis claims need objective imaging behind them. This becomes the main gate deciding which claims survive, and it is still in force.
The Judicial Panel creates MDL 3163 for NAION claims, assigning it to Judge Marston alongside the digestive docket. The two proceed on separate schedules.
Judge Marston denies Eli Lilly’s bid to restrict testimony from former FDA Commissioner Dr. David Kessler on gastric emptying and label adequacy. Widely read as a procedural win for claimants ahead of the expert hearing.
Both sides present non-adversarial scientific briefings to the court on how GLP-1 drugs affect blood flow to the optic nerve and how NAION is diagnosed.
The decisive moment for MDL 3094. The court hears challenges to the plaintiffs’ causation experts. If they are allowed to testify, the docket moves toward bellwether trials and settlement pressure builds. If not, a large share of claims could be dismissed.
The honest answer is that nobody knows yet — and that is worth understanding before you talk to anyone who says otherwise.
A hospital admission that resolved is valued very differently from gastroparesis you still live with, or sight you will not get back.
A gastric emptying study, imaging, surgical notes and a clear treatment history do more for a claim than anything else on this list.
Medical bills, lost income, reduced earning capacity and the cost of care you will still need. These are documented, not estimated.
Longer, well-documented use with a clear before-and-after in your records makes causation easier to argue.
No GLP-1 case has reached a jury. No settlement has been announced. There is no compensation grid, no tiered matrix and no average payout — because nothing has been paid.
Sites publishing “expected Ozempic settlement amounts” are extrapolating from unrelated pharmaceutical cases. Those figures are marketing, not forecasting, and they set expectations that the September hearing could dismantle overnight.
What we will tell you is where your claim sits, what evidence it is missing and what the realistic timeline looks like.
Get a straight assessment
You are not filing today. You are finding out whether you have a case, which costs nothing and closes no doors.
Which drug, what injury, roughly when it started and where you live. No documents needed yet.
Digestive injuries go to MDL 3094, vision loss to MDL 3163. We also check your state’s deadline before anything else.
A partner firm collects prescription history, diagnosis records and any gastric emptying study. They can request records you no longer hold.
If it qualifies, your claim is filed individually into the MDL. You sign a contingency agreement — nothing up front, no fee without a recovery.
Nothing up front, and nothing at all unless you win. Here is exactly how the money works, so there are no surprises later.
No consultation fee, no retainer, no hourly billing. Ozempic lawyers take these cases on a contingency fee, which means their payment comes out of a recovery and nowhere else. If your case does not win, you owe no legal fee.
Contingency fees in mass tort cases commonly run in the range of a third to forty percent of a recovery, and the exact figure has to be written into the agreement you sign. Read that number before you sign, and ask how case costs are handled separately.
There is no charge to be connected with an Ozempic attorney through us, and no obligation to hire anyone who calls you. If you would rather take the information and find your own lawyer, that is a completely reasonable thing to do.
Ozempic cases are filed in federal court in Pennsylvania no matter where you live — but your filing deadline is set by your own state, and it is the thing most likely to cost you a claim. Pick your state and we will check it first.
Why your state still matters. Statutes of limitation run from one to several years depending on where you live, and wrongful death claims run on a separate clock. Some states also apply a discovery rule that can start the clock later. We check yours before anything else happens.
Check my state’s deadlineBoth GLP-1 dockets are still accepting claims, and that is genuinely good news. But the filing window that matters is the one set by your own state’s statute of limitations, and it started running when you were injured — or when you reasonably should have connected the injury to the drug.
Most states allow two to three years. A few allow one. Wrongful death claims run on a separate clock from the date of death. Miss it and the strongest case in the docket is worth nothing.
Tell us your state, the drug and roughly when the injury started. We will tell you whether you are still inside the deadline before anything else happens.
Check my deadline Free · No obligation · About 30 secondsA claim specialist will check your situation against both GLP-1 dockets and confirm whether you are still inside your state’s filing deadline.
About 30 seconds · Free claim service · No obligation
A claim specialist will call to verify your potential claim, confirm which GLP-1 docket it belongs in, and check whether you are still inside your state’s filing deadline.
People who came to us after a GLP-1 injury and wanted to know where they stood.
Trusted by thousands of injured people nationwide
I was hospitalised three times before anyone mentioned the drug might be the cause. They walked me through what records I needed and never rushed me.
The questions people actually ask before they call a lawyer.
Detail pages for the questions this one only summarises.
What drives value in a GLP-1 claim, why no payout figures exist yet, and what September could change.
Read moreThe evidence you need, the records to preserve now, and what happens after you sign.
Read moreA step-by-step eligibility check covering drug, injury, evidence and your state’s deadline.
Read moreDated entries as the litigation moves. Newest first, refreshed as orders are entered.
Read moreThe MDL 3163 track in detail — the research, the diagnosis and who can bring a claim.
Read moreHow these claims are built and why the gastric emptying study decides so many of them.
Read moreYou pay nothing unless we win your case.
Your information is safe with us.
Our lawyers fight for maximum compensation.